These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39182943)

  • 1. A randomized, open-label phase II study on the preventive effect of goshajinkigan against peripheral neuropathy induced by paclitaxel-containing chemotherapy: The OLCSG2101 study protocol.
    Nakamura N; Makimoto G; Tanaka T; Kato Y; Oze I; Kozuki T; Yokoyama T; Ichikawa H; Kuyama S; Hara N; Maeda Y; Hotta K
    Respir Investig; 2024 Sep; 62(5):897-900. PubMed ID: 39182943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the Traditional Japanese Medicine Goshajinkigan in Preventing Paclitaxel-Induced Peripheral Neuropathy: A Multicenter Randomized Comparative Trial.
    Matsumura Y; Futagami M; Baba T; Soeda S; Watari H; Terada Y; Tokunaga H; Nagase S; Nakanishi T; Kaiho M; Yokoyama Y
    Integr Cancer Ther; 2024; 23():15347354241278635. PubMed ID: 39256982
    [No Abstract]   [Full Text] [Related]  

  • 3. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
    Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
    BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
    Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
    BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Kuriyama A; Endo K
    Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
    Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
    Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: protocol for a systematic review and meta-analysis.
    Hoshino N; Hida K; Ganeko R; Sakai Y
    Int J Colorectal Dis; 2017 May; 32(5):737-740. PubMed ID: 27889823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy.
    Cascella M; Muzio MR
    J Integr Med; 2017 Mar; 15(2):77-87. PubMed ID: 28285612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
    Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind, randomized study.
    Park SJ; Yim GW; Paik H; Lee N; Lee S; Lee M; Kim HS
    J Gynecol Oncol; 2021 Sep; 32(5):e73. PubMed ID: 34132071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
    Kang YJ; Yoon CI; Yang YJ; Baek JM; Kim YS; Jeon YW; Rhu J; Yi JP; Kim D; Oh SJ
    BMC Cancer; 2023 Jun; 23(1):570. PubMed ID: 37340369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial).
    Aghili M; Taherioun M; Jafari F; Azadvari M; Lashkari M; Kolahdouzan K; Ghalehtaki R; Abdshah A
    Support Care Cancer; 2024 Jul; 32(8):493. PubMed ID: 38976095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial.
    Wang XQ; Liu J; Lin HS; Hou W
    Trials; 2016 Mar; 17(1):124. PubMed ID: 26956875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electroacupuncture use for treatment of taxane-induced peripheral neuropathy in patients with breast cancer: protocol for a pilot, randomised, blinded, sham-controlled trial (EA for CIPN).
    Choi V; Park SB; Lacey J; Kumar S; Heller G; Grimison P
    BMJ Open; 2024 Jan; 14(1):e076391. PubMed ID: 38195173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Hoshino N; Ganeko R; Hida K; Sakai Y
    Int J Clin Oncol; 2018 Jun; 23(3):434-442. PubMed ID: 29270698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effect of N-acetylcysteine on the prevention and amelioration of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.
    Khalefa HG; Shawki MA; Aboelhassan R; El Wakeel LM
    Breast Cancer Res Treat; 2020 Aug; 183(1):117-125. PubMed ID: 32601973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol.
    Jang CE; Jung MS; Sohn EH; Kim M; Yoo HS; Bae K; Kim JR; Lee JS
    Trials; 2018 Sep; 19(1):526. PubMed ID: 30268158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the publication of Clinical Guidelines for the Management of Chemotherapy-Induced Peripheral Neuropathy on the Administration Preferences of Oncology Specialists: Japanese Association of Supportive Care in Cancer.
    Hirayama Y; Yoshida Y; Mori M; Tamura K
    Jpn J Clin Oncol; 2020 Aug; 50(8):897-902. PubMed ID: 32424420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action.
    Matsumura Y; Yokoyama Y; Hirakawa H; Shigeto T; Futagami M; Mizunuma H
    Mol Pain; 2014 Sep; 10():61. PubMed ID: 25240613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.